CG
LXRX icon

Cutler Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Cutler Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-66,500
Closed -$7K – 5468
2017
Q3 		$7K Sell
66,500
-22,700
-25% -$335K ﹤0.01% 4108
2017
Q2 		$139K Sell
89,200
-11,200
-11% -$173K 0.01% 1583
2017
Q1 		$19K Buy
100,400
+92,900
+1,239% +$1.38M ﹤0.01% 3379
2016
Q4 		$1K Sell
7,500
-15,300
-67% -$245K ﹤0.01% 6043
2016
Q3 		$60K Buy
22,800
+1,100
+5% +$17.7K ﹤0.01% 2279
2016
Q2 		$54K Buy
21,700
+1,400
+7% +$19K ﹤0.01% 2278
2016
Q1 		$43K Buy
20,300
+5,000
+33% +$52.4K ﹤0.01% 2486
2015
Q4 		$25K Buy
+15,300
New +$188K ﹤0.01% 3181

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $25.6B AUM 30.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Cutler Group's LXRX Position: Q4 2017 in Review

Cutler Group sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2017, closing a stake of 62,210 shares — an estimated $646K sold.

Cutler Group first reported a position in LXRX in Q4 2015 and held it in 8 quarters. The position peaked at $764K in Q3 2017. 133 funds tracked by Wall St. Rank hold LXRX as of Q4 2017.

  • Cutler Group reported no remaining Lexicon Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Cutler Group sold 62,210 Lexicon Pharmaceuticals shares in Q4 2017, an estimated $646K.
  • Cutler Group first reported a position in Lexicon Pharmaceuticals in Q4 2015 and held it in 8 quarters.
  • Cutler Group's Lexicon Pharmaceuticals position peaked at $764K in Q3 2017.
  • 133 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2017.

Based on Cutler Group's 13F filing for Q4 2017, filed 17 Jan 2018.